Exclusive Summary

• **Dual Anti-Resistance Mechanism**: UB136 features a "Bispecific Antibody (BsAb) + Dual-payload" design, utilizing a single linker to conjugate two payloads with distinct mechanisms. This effectively addresses tumor heterogeneity and overcomes drug resistance often seen in single-payload ADCs.
• **Widened Therapeutic Window**: By leveraging BsAb for enhanced internalization (1+1>2) and tumor selectivity, combined with the synergistic cytotoxicity of dual payloads, UB136 is designed to significantly lower the Minimum Effective Dose (MED) and reduce systemic toxicity.
• **CMC and Development Superiority**: Powered by the proprietary "One Linker, Two Payloads" (L2P) platform, UB136 achieves dual-payload conjugation in a single step. This offers superior homogeneity and CMC controllability compared to co-administration or complex dual-linker technologies, representing a high-value First-in-class/Best-in-class asset.

Asset Materials

Contact Us for Full Materials